COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study

BACKGROUND: By June 30, 2022, 92·6% of the Chilean population older than 18 years had received a full primary SARS-CoV-2 vaccine series, mostly with CoronaVac (Sinovac Biotech), and 78·4% had received a booster dose, mostly heterologous with BNT162b2 (Pfizer–BioNTech) and ChAdOx1 (AstraZeneca). We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauré, Denis, O'Ryan, Miguel, Torres, Juan Pablo, Zuñiga, Marcela, Soto-Rifo, Ricardo, Valiente-Echeverría, Fernando, Gaete-Argel, Aracelly, Neira, Ignasi, Saavedra, Vicente, Acevedo, Mónica L, Archila, Carmen, Acuña, Fernando, Rain, Manuel, Basso, Leonardo J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883018/
https://www.ncbi.nlm.nih.gov/pubmed/36716754
http://dx.doi.org/10.1016/S2666-5247(22)00290-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883018/
https://www.ncbi.nlm.nih.gov/pubmed/36716754
http://dx.doi.org/10.1016/S2666-5247(22)00290-7

Ejemplares similares